#Paris #France #AI Drug Discovery #Iktos #EIC Accelerator

Iktos Secures EIC Accelerator Grant

Iktos, a pioneering player in the field of AI-driven drug discovery, has recently been awarded a significant grant of €2.5 million from the European Innovation Council (EIC) Accelerator. This funding is set to propel the company's ambitious plans to enhance its AI and robotics synthesis automation technology. Additionally, there is potential for an extra €5 million from the EIC, aiming to substantially impact the future of drug discovery.

The main objective of this investment is to create a fully integrated platform that combines AI-based molecular generation, automated synthesis processes, and high-precision biological testing. This approach is poised to streamline and accelerate the drug discovery process, making it faster and more efficient than ever before. Over the next two years, Iktos aims to expand its already robust platform, especially following its recent acquisition of Synsight and its proprietary MTBench technology. This advanced tool is renowned for its capacity to facilitate high-precision biological screenings in environments that closely mirror real biological conditions.

Transforming Drug Discovery

The innovation at Iktos lies in its ability to integrate various stages of the Drug-Make-Test-Analyze (DMTA) cycle through the utilization of advanced AI technologies. Each phase of this cycle is driven by AI, which dynamically incorporates real experimental data into the generative AI system with every iteration. By consistently refining predictions with actual feedback, the platform not only enhances precision but also accelerates the convergence of viable drug candidates, significantly cutting down the time required for drug development.

Yann Gaston-Mathé, CEO of Iktos, expressed his gratitude for this recognition: _"Receiving this support from the European Innovation Council is a significant honor. It empowers us to enhance our AI and robotics platform to accelerate the discovery of innovative treatments, which can bring healthier outcomes for patients. Furthermore, it reinforces Europe’s commitment to ethical AI advancements that align with essential strategy and priorities."_

Aligning with EIC Challenges

Iktos's platform is not only revolutionary in its technology but is also aligned with the EIC Accelerator Challenge, which emphasizes human-centric generative AI development made in Europe. This synergy boosts the potential of AI in drug discovery while adhering to transparency and ethical standards.

The platform enables researchers to focus more on strategic decision-making, while the AI optimizes molecular designs and robotics efficiently manage the synthesis. Iktos's AI ensures that the molecules generated are not only theoretically promising but also feasible for synthetic production. Through a combination of virtual synthesis and high-quality datasets, all validated by expert oversight, the platform offers a dependable pathway to robust drug development.

About Iktos

Iktos stands at the forefront of artificial intelligence and robotics in drug discovery. Its generative AI technology effectively designs molecules using in silico methods, tailored to satisfy all vital success criteria required for a discovery project. This technology is accessible as Software as a Service (SaaS) and is also available through strategic partnerships with pharmaceutical organizations. Iktos has successfully completed over 60 projects to date and is actively pursuing its pipeline of drug candidates targeting oncology, obesity and metabolism, inflammatory, and autoimmune disorders. The company had previously raised €15.5 million in a Series A financing round, led by M Ventures and Debiopharm Innovation, alongside contributions from Omnes Capital. For further information, please visit Iktos.ai.